Orexo AB (publ) (ORXOF)
| Previous close | 2.5800 |
| Open | 2.5800 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 2.5800 - 2.5800 |
| 52-week range | 2.3500 - 4.0244 |
| Volume | |
| Avg. volume | 15 |
| Market cap | 60.858M |
| Beta (5Y monthly) | 0.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Orexo's partner Trinity Health today announces the availability of vorvida® and deprexis® to patients
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces the Integrated Healthcare System, Trinity Health in North Dakota, in partnership with Orexo, is expanding patient access to digital therapeutics. Trinity Health will now offer Orexo's evidence-based digital therapies vorvida® and deprexis® to help patients manage depression and excessive drinking.
- PR Newswire
First patent issued in Europe for Orexo's adrenaline product OX640
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the European Patent Office (EPO) has granted the first European patent specifically relating to OX640, Orexo's nasal adrenaline rescue medication based on the amorphOX® drug delivery platform.
- PR Newswire
Orexo to participate in Pareto Securities´ 13th Annual Healthcare Conference
Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), which develops improved pharmaceuticals and evidence-based digital therapeutics primarily targeting the US market where its commercial organization is located, today announces the company will participate in Pareto Securities' 13th Annual Healthcare Conference, that takes place on September 7-8, 2022, at Sergel Hub, Sveavägen 10 A, Stockholm, Sweden.
